Daraxonrasib doubles survival in metastatic pancreatic cancer trials
Daraxonrasib, a new oral RAS(ON) inhibitor developed by Revolution Medicines, has shown significant clinical potential in treating metastatic pancreatic ductal adenocarcinoma (PDAC). In clinical trials, the drug doubled median overall survival to 13.2 months, compared to 6.7 months for patients receiving standard chemotherapy. This represents a 60 percent reduction in the risk of death.
The drug works as a molecular glue, binding to RAS proteins in their active state to silence the master switch that drives uncontrolled cell growth in approximately 90 percent of pancreatic cancers. While 96 percent of patients in an early-stage trial experienced side effects, most were categorized as low-grade, including nausea, skin rashes, diarrhea, and mouth inflammation.
The FDA has accepted the company’s new drug application for review as of July 22. Additionally, an expanded access protocol has been established, allowing eligible patients with metastatic pancreatic cancer who have no other satisfactory alternatives to access the investigational treatment outside of formal clinical trials.
Entities
FDA · KRAS · RAS(ON) inhibitors · Revolution Medicines · daraxonrasib
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [○ 1 SOURCE] 96 percent of the 168 patients in an early-stage trial experienced treatment-related side effects. www.memesita.com
- [○ 1 SOURCE] The FDA accepted the new drug application for daraxonrasib for review on July 22. www.medicaldaily.com
- [● 3 SOURCES] Daraxonrasib belongs to a new class of medications known as RAS(ON) inhibitors. ma-clinique.fr · www.memesita.com · www.news-medical.net
- [○ 1 SOURCE] Common side effects of the drug include skin rashes, nausea, mouth inflammation, and diarrhea. www.memesita.com
- [● 4 SOURCES] In clinical trials, daraxonrasib doubled median overall survival to 13.2 months compared to 6.7 months for those on standard chemotherapy. ma-clinique.fr · www.memesita.com · www.medicaldaily.com · www.news-medical.net
- [○ 1 SOURCE] The drug resulted in a 60 percent reduction in the risk of death in the Phase 3 RASolute 302 trial. www.medicaldaily.com
- [● 2 SOURCES] Revolution Medicines developed the drug daraxonrasib. www.memesita.com · www.medicaldaily.com
- [○ 1 SOURCE] The clinical trial included patients with metastatic pancreatic ductal adenocarcinoma regardless of their RAS mutation status. www.medicaldaily.com